Delcath Systems Inc (DCTH)

NASDAQ
Currency in USD
15.340
-0.300(-1.92%)
Closed·
After Hours
15.640+0.300(+1.956%)
·
DCTH Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
DCTH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.12015.570
52 wk Range
7.17018.230
Key Statistics
Edit
Prev. Close
15.64
Open
15.3
Day's Range
15.12-15.57
52 wk Range
7.17-18.23
Volume
316.42K
Average Volume (3m)
489.62K
1-Year Change
101.05%
Book Value / Share
2.4
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DCTH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.078
Upside
+56.96%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Delcath Systems Inc News & Analysis

Show more

Delcath Systems Inc Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.

Delcath Systems Inc Earnings Call Summary for Q1/2025

  • Delcath Systems Q1 2025 EPS of $0.03 and revenue of $19.8M beat forecasts; shares surge 15.18%
  • Net income improved to $1.1M from $11.1M loss; gross margins up to 86% from 71% in 2024
  • Company aims to activate 30 treatment centers by year-end; plans to increase SG&A by 60% and R&D by 150%
  • CEO confident in growth trajectory; highlights potential impact of clinical trial data on progression-free survival
  • Analysts set price targets between $21-$25; stock delivered 110.52% return over past year
Last Updated: 2025/05/08, 15:40
Read Full Transcript

Compare DCTH to Peers and Sector

Metrics to compare
DCTH
Peers
Sector
Relationship
P/E Ratio
−37.6x−14.6x−0.4x
PEG Ratio
−0.46−0.470.00
Price/Book
6.7x7.0x2.6x
Price / LTM Sales
9.9x4.2x3.1x
Upside (Analyst Target)
53.2%69.1%51.1%
Fair Value Upside
Unlock−12.0%8.9%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.078
(+56.96% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
0.03 / 0.02
Revenue / Forecast
19.80M / 15.51M
EPS Revisions
Last 90 days

DCTH Income Statement

FAQ

What Is the Delcath Systems (DCTH) Stock Price Today?

The Delcath Systems stock price today is 15.34

What Stock Exchange Does Delcath Systems Trade On?

Delcath Systems is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Delcath Systems?

The stock symbol for Delcath Systems is "DCTH."

What Is the Delcath Systems Market Cap?

As of today, Delcath Systems market cap is 534.23M.

What Is Delcath Systems's Earnings Per Share (TTM)?

The Delcath Systems EPS (TTM) is -0.46.

When Is the Next Delcath Systems Earnings Date?

Delcath Systems will release its next earnings report on 10 Aug 2025.

From a Technical Analysis Perspective, Is DCTH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Delcath Systems Stock Split?

Delcath Systems has split 5 times.

How Many Employees Does Delcath Systems Have?

Delcath Systems has 96 employees.

What is the current trading status of Delcath Systems (DCTH)?

As of 15 Jun 2025, Delcath Systems (DCTH) is trading at a price of 15.34, with a previous close of 15.64. The stock has fluctuated within a day range of 15.12 to 15.57, while its 52-week range spans from 7.17 to 18.23.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.